All of those in a recent small trial of individuals recently infected with genotype 1 of hepatitis C virus (HCV) were cured after just six weeks of treatment with Harvoni (ledipasvir/sofosbuvir), Healio reports.
Researchers presented findings from the Phase II prospective, open-label, multicenter, single-arm pilot study at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston. They also published their findings in The Lancet Infectious Diseases.
Twenty participants were recruited between November 2014 and November 2015. Eleven of them had genotype 1a and nine had genotype 1b.
All the participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).
The treatment was well tolerated. No one had to stop taking Harvoni because of drug-related serious adverse health events.
To read the Healio article, click here.
To read the study abstract, click here.